What the FDA labels say about taking them together
Moxifloxacin and ziprasidone
Ziprasidone's FDA label of July 20, 2026 names moxifloxacin in its contraindications section; moxifloxacin's label does not name ziprasidone itself but warns about its class (Atypical antipsychotics). The ziprasidone label: “… thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron mesylate, probucol or tacrolimus. …”
Check it at the source: the moxifloxacin FDA label on DailyMed (effective March 17, 2026, Macleods Pharmaceuticals Limited); the ziprasidone FDA label on DailyMed (effective July 20, 2026, Apotex Corp.).
What does the moxifloxacin label say about ziprasidone?
Moxifloxacin's label does not name ziprasidone itself; it warns about its class (Atypical antipsychotics):
Moxifloxacin label, warnings and precautionsKnown prolongation of the QT interval Ventricular arrhythmias including torsade de pointes because QT prolongation may lead to an increased risk for these conditions Ongoing proarrhythmic conditions, such as clinically significant bradycardia and acute myocardial ischemia, Uncorrected hypokalemia or hypomagnesemia Class IA (for example, quinidine, procainamide) or Class III (for example, amiodarone, sotalol) antiarrhythmic agents Other drugs that prolong the QT interval such as cisapride, erythromycin …
Moxifloxacin label, warnings and precautionsPharmacokinetic studies between moxifloxacin and other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants have not been performed.
Source: FDA drug label (Moxifloxacin), Macleods Pharmaceuticals Limited, effective March 17, 2026 (SPL set 182ecd0f-714f-42f0-9b16-fb604cf15786), via openFDA; the full label on DailyMed
What does the ziprasidone label say about moxifloxacin?
Ziprasidone label, contraindicationsTherefore, ziprasidone should not be given with: dofetilide, sotalol, quinidine, other Class Ia and III anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron mesylate, probucol or tacrolimus. other drugs that have demonstrated QT prolongation as one of their pharmacodynamic effects and have this effect described in the full prescribing information as a contraindication or a boxed or bolded warning [see Warnings and Precautions (5.3) ].
Source: FDA drug label (ziprasidone hydrochloride), Apotex Corp., effective July 20, 2026 (SPL set ccfd5ba2-7271-f3dd-4c98-7418c1a4b54a), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Moxifloxacin | Ziprasidone | |
|---|---|---|
| Labeled for | Bacterial infections | Bipolar disorder, Schizophrenia |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $1.60 per mL 0.5% eye drops | $0.269 per capsule 20 mg capsule |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once